

Managing ACS patients: importance of dual antiplatelet therapy

Robert C. Welsh, MD, FRCPC
Associate Professor of Medicine
Interventional Cardiologist
Chair, Vital Heart Response


Director, University of Alberta Cardiology Residency Training Program
Co-director, U of A Chest Pain Program



CURE


ACS (NSTEMI)

Primary End Point: MI/Stroke/CV Death (N=12,562*)




* Study subjects had ACS (UA/non-Q-wave MI).
† Other standard therapies were used as appropriate.
‡ PLAVIX Prescribing Information.
CURE Trial Investigators. *N Engl J Med.* 2001;345:494-502.

CURE Benefit of Clopidogrel Therapy at Various Time Intervals





Yusuf S, et al for the CURE Trial Investigators. *Circulation* 2003; 107:966.

CURE: Relation Between Safety and ASA Dosage



* On top of standard therapy (including ASA).
Clopidogrel Prescribing Information.



STEMI

COMMIT: Study Design

TREATMENT: Clopidogrel 75 mg daily vs placebo (ASA 162 mg daily in both groups)


INCLUSION: Suspected acute MI (ST change or LBBB) within 24 h of symptom onset

EXCLUSION: Primary PCI or high-risk of bleeding

1° OUTCOMES: Death and death, re-MI or stroke up to 4 weeks in hospital (or prior discharge)

Mean treatment and follow-up: 16 days

Chen Z. Presentation at ACC 2005; Orlando, FL; March 9, 2005.



Use of antiplatelets agents in CAD

High-risk patients without diagnosis of CAD: low dose ASA (if contraindicated then clopidogrel)

Stable atherothrombosis patients: low dose ASA (if contraindicated then clopidogrel)

Post PCI: low dose ASA + clopidogrel for 12 months

- If drug eluting stent – >12 months but discuss with Cardiologist

Acute coronary syndrome: low dose ASA + clopidogrel for 12 months

High risk NSTEMI patients: low dose ASA + clopidogrel for 12 months plus consider early cardiac cath and IIb/IIIa receptor blockers

STEMI patients: low dose ASA + clopidogrel duration dependent on in-hospital risk stratification

- For Primary PCI consider IIb/IIIa receptor blockers